{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:47Z","timestamp":1789506167914,"version":"build-2803163510"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anitens are a family of oral N-terminal domain inhibitors of the androgen receptor (AR). In prostate cancer, they may help overcome AR resistance mechanisms at the ligand-binding domain, which is the binding site of approved androgen receptor pathway inhibitors like enzalutamide. Masofaniten (EPI-7386) is a next-generation aniten with promising activity and safety in patients with metastatic castrate-resistant prostate cancer (mCRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this investigator-initiated, phase II, single-arm, single-institution trial, patients with treatment-na\u00efve metastatic hormone-sensitive prostate cancer (mHSPC) were enrolled in a Simon 2-stage study design to receive the combination of masofaniten 600\u2009mg BID and enzalutamide 160\u2009mg daily with androgen deprivation therapy (ADT). The study was designed to enroll 35 patients (13 patients in stage 1, then 22 patients in stage 2). The trial would move to stage 2 if 9 or more subjects achieved a biochemical response at 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen patients were screened and enrolled into stage 1. Five were African American, and 8 were Caucasian. The median age was 68\u2009years (range 52-75) at time of enrollment. Median follow-up time was 9.9\u2009months (range 7.7-13.6). Ten of 13 patients (77% with 95% CI: 50%-92%) achieved a PSA &amp;lt;0.2\u2009ng\/mL at 6\u2009months, achieving the threshold to move on to stage 2. Only one patient had disease progression to mCRPC and died of disease at the time of data cutoff. Patients continued enzalutamide and ADT after trial closure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of masofaniten and enzalutamide for treatment-na\u00efve mHSPC did show efficacy and had an acceptable safety profile. These results support further investigation of the dual AR blockade in mHSPC (ClinicalTrials.gov Identifier: NCT06312670).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf434","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:44:38Z","timestamp":1767098678000},"source":"Crossref","is-referenced-by-count":4,"title":["EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-na\u00efve metastatic hormone-sensitive prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-6174","authenticated-orcid":false,"given":"Albert","family":"Jang","sequence":"first","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Fowler","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Helminiak","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamsa L S","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Pasucal","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9490-8034","authenticated-orcid":false,"given":"Victoria","family":"Delong","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1711-3155","authenticated-orcid":false,"given":"Jeffrey Y","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-3278","authenticated-orcid":false,"given":"Tanya","family":"Jindal","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-8670","authenticated-orcid":false,"given":"Abby L","family":"Grier","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi R","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hislop","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cesano","sequence":"additional","affiliation":[{"name":"ESSA Pharma Inc., South San Francisco , CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Villaluna","sequence":"additional","affiliation":[{"name":"ESSA Pharma Inc., South San Francisco , CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Younginger","sequence":"additional","affiliation":[{"name":"ESSA Pharma Inc., South San Francisco , CA 94080,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Wolff","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Richey","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bray","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Garcia","sequence":"additional","affiliation":[{"name":"Gilmour Academy , Cleveland, OH 44040,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Adamowicz","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center at Firelands Regional Medical Center , Sandusky, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Reese","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center at Firelands Regional Medical Center , Sandusky, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-490X","authenticated-orcid":false,"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]},{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]},{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2069","authenticated-orcid":false,"given":"Christopher E","family":"Wee","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]},{"name":"Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Margevicius","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-5218","authenticated-orcid":false,"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Mendiratta","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4999-6733","authenticated-orcid":false,"given":"Iris Y","family":"Sheng","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7555","authenticated-orcid":false,"given":"Jason R","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Case Comprehensive Cancer Center , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026020200312162100_oyaf434-B1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in titan patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"2026020200312162100_oyaf434-B2","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase iii aranote trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026020200312162100_oyaf434-B3","doi-asserted-by":"crossref","first-page":"e258751","DOI":"10.1001\/jamanetworkopen.2025.8751","article-title":"Enzalutamide and prostate-specific antigen levels in metastatic prostate cancer: a secondary analysis of the arches randomized clinical trial","volume":"8","author":"Azad","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026020200312162100_oyaf434-B4","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2024.42.16_suppl.5079","article-title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: landmark analysis of enzamet (anzup 1304)","volume":"42","author":"Laughlin","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"2026020200312162100_oyaf434-B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur Urol"},{"key":"2026020200312162100_oyaf434-B6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2021.39.6_suppl.102","article-title":"Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (m1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mhspc (m0): post hoc analysis of the phase iii arches trial","volume":"39","author":"Azad","year":"2021","journal-title":"JCO"},{"key":"2026020200312162100_oyaf434-B7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1634\/theoncologist.2016-0161","article-title":"Targeting the n-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer","volume":"21","author":"Antonarakis","year":"2016","journal-title":"Oncologist"},{"key":"2026020200312162100_oyaf434-B8","year":"2024"},{"key":"2026020200312162100_oyaf434-B9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bju.16449","article-title":"Targeted investigational treatment analysis of novel anti-androgen (titan) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy","volume":"134","author":"Merseburger","year":"2024","journal-title":"BJU Int"},{"key":"2026020200312162100_oyaf434-B10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: Analyses of the randomized phase 3 Arasens study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"2026020200312162100_oyaf434-B11","doi-asserted-by":"crossref","first-page":"e1360","DOI":"10.1097\/01.JU.0001110200.18879.65.07","article-title":"Ip26-07 ultra-low PSA response (&lt;0.02 ng\/ml) with darolutamide plus ADT in aranote correlates with greatly improved clinical outcomes","volume":"213","author":"Shore","year":"2025","journal-title":"The Journal of Urology"},{"key":"2026020200312162100_oyaf434-B12","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2025.43.16_suppl.5002","article-title":"Prognostic significance of PSA&gt;0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): a multinational real-world analysis of the ironman registry","volume":"43","author":"Ong","year":"2025","journal-title":"JCO"},{"key":"2026020200312162100_oyaf434-B13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","article-title":"Prognostic and predictive role of spop mutations in prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Pedrani","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026020200312162100_oyaf434-B14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf434\/66159749\/oyaf434.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf434\/66159749\/oyaf434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf434\/66159749\/oyaf434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T05:31:28Z","timestamp":1770010288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf434\/8407307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf434","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,30]]},"article-number":"oyaf434"}}